Efficacy of Oral Terbinafine with Meglumine Antimoniate/ Glucantime (Intalesional) vs Glucantime I/L alone in Treatment of Cutaneous Leishmaniasis
DOI:
https://doi.org/10.63682/jns.v14i32S.9978Keywords:
efficacy, intralesional meglumine antimonite injections, cutaneous leishmaniasisAbstract
Introduction: Leishmaniasis is a chronic vector-born protozoan disease, occurring in various presentations from the self-limiting, even self healing cutaneous nodular or ulcerated lesion to lifethreatning visceral disease, each caused by one of the species of the genus leishmania. It is the major health problem worldwide. It also appears to be an emerging disease in the various parts of Pakistan especially in rural areas& endemic in Bolochistan, Interior Sindh, Multan, Tribal area (refugees from Afghanistan) & western border of Pakistan.
Objective: To compare the efficacy of oral terbinafine with meglumine antimoniate/(Glucantime) intralesional verses Glucantime (intralesional) alone for treatment of cutaneous Leishmaniasis.
Methodology: This Randomized control trails study was carried out at the Dermatology Department Lady Reading Hospital Peshawar for duration of six months from June 2023 to November 2023. In this study a total of 102 patients were included by taking 51 in each group, using 80% efficacy of oral Terbinafine + Glucantime, 52.9% efficacy of Glucantime alone, 95% confidence level & 90% power of test (Non Probability Sampling) technique was used for sample collection.
Results: Our study shows that in Group A mean age was 33 years with SD ± 3.621 and in Group B mean age was 32 years with SD ± 3.315. In Group A 68% patients were male and 32% patients were female. Where as in Group B 65% patients were male and 18(35%) patients were female. Group A (oral terbinafine 250 mg daily + Glucantime I/L) was effective in (82%) patients where as Group B (Glucantime I/L once) was effective in (60%) patients.
Conclusion: Our study concludes that oral terbinafine with Glucantime (intralesional) was more effective as compare to Glucantime (intralesional) alone for treatment of cutaneous Leishmaniasis
Downloads
References
1. Khan S, Khan A, Nisa I. Frequency of cutaneous leishmaniasis among clinically suspected cases, visiting tertiary care hospital of Peshawar.JZMC. 2009;3.2:282-5
2. Khan JS, Muneeb S cutaneous leishmaniasis in Pakistan;how to go about it.JPMI.2011;18(4):701-7
3. Yasmin R, Khan I, Ahmad AS. Response to treatment of cutaneous leismaniasis with intralesional chloroquine vs intralesional meglumine animoniate.JPAD.2011;21(4):270-5
4. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD,Pompeu MM.LHigh-dose oral Flucanazole therapy effective for cutaneous Leishmanasis due to Leishmania(Vianna) brazillence.C I D2011;53(7):693-5
5. Singh N, Kumar M, Singh KR. Leishmaniasis:Current status of available drugs and new potential drug targets.APJTM. 2012:485-97
6. Ebrahimia S, Asilian A,Faghihi G Comparative study on Glucantime and oral Terbinafine along with systemic Glucantime on cutaneous Leishmaniasis.JIMS 2011;28.118.1-7.7
7. Chawla B, Madhubala R. Drug targets in Leishmania.JPD. 2010;34(7):1-13.
8. Badamdan KA, Tallab TM, Johargi H, Nourad MM, Ibrahim K,Sherbini AH et al. Tebinafine in the treatment of Cutanous Leishmaniasis:a pilot study.Int J dermatol.1997:36(1):59-60
9. Abdullah F, Riad H. Cutaneous Leismaniasis treated with Terbinafine (lamasil):a case report. GJDV.2002;9.2.38-40.
10. Mitropoulos P, Konidus P, Durkin-konidas M. New world cutaneous Leishmaniasis;Updated review of future diagnosis & treatment.JAAD.2010;63(2).309-22
11. Valez I,Lopez L,Sanchez X,Mestra L,Rojas C,Rodriguez E.Efficacy of Miltifosin for treatment of American Cutaneous Leishmaniasis.Am.J.Trop.Med.Hyg.2010;83(2).351-6 Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycine with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 2005;44:1064–5
12. Sundar S, Singh J, Singh VK, Agrawal N, Kumar R. Current and emerging therapies for the treatment of leishmaniasis. Expert opinion on orphan drugs. 2024 Dec 31;12(1):19-32.
13. Mengstie TA, Endale HT, Mulaw T, Abdella AM, Mohammed R, Malik T, Dessie G. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. PLoS One. 2021 Oct 1;16(10):e0257229.
14. Ebrahimian S, Asilian A, Faghihi G. A Comparetaive study on glucantime and oral terbinafine along with systemic on glucantime on cutaneus Leishmaniasis. J Isfahan Med School. 2011;28(118):1246-52.
15. Carresi C, Ferrucci CF, Mangano C, Coppoletta AR, Cardamone A, Musolino V, Gliozzi M, Mollace V, Britti D. Efficacy of meglumine antimoniate treatment on Boxer Leyshmania infantum skin lesions-Case Report. Frontiers in Veterinary Science. 2025 Jun 30;12:1600004.
16. Abdullah F, Riad H. Cutaneous Leismaniasis treated with Terbinafine (lamasil):a case report. GJDV.2002;9.2.38-40.
17. Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycine with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 2005;44:1064–5
18. Alotaibi H, Aldossari A, Alnasser S. Impetiginous cutaneous Leishmaniasis after COVID-19 infection in a patient with poor cardiac profile: A case report and literature review. Tropical Medicine and Infectious Disease. 2023 Sep 10;8(9):443.
19. Comparison of Effectiveness of Oral Fluconazole and Intralesional Glucantime in the Treatment of Cutaneous Leishmaniasis. (2024). Medical Forum Monthly, 32(6).
20. Sattar F, Akram S, Akhtar A, Almas U, Tahir R, Nawaz S. Efficacy of oral zinc sulphate compared with intralesional meglumine antimoniate injection (glucantime) in the treatment of cutaneous leishmaniasis.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
